Neurofibromin deficiency-associated transcriptional dysregulation suggests a novel therapy for tibial pseudoarthrosis in NF1

Journal of Bone and Mineral Research

Volumn 29, Issue 12, 2014, Pages 2636-2642

  Paria, Nandina ^a   Cho, Tae Joon ^b   Choi, In Ho ^b   Kamiya, Nobuhiro ^a,c   Kayembe, Kay ^d   Mao, Rong ^e,f   Margraf, Rebecca L ^e   Obermosser, Gerlinde ^d   Oxendine, Ila ^a   Sant, David W ^e   Song, Mi Hyun ^g   Stevenson, David A ^f   Viskochil, David H ^f   Wise, Carol A ^a,c,h   Kim, Harry K W ^a,c   Rios, Jonathan J ^a,c,h  

^a TEXAS SCOTTISH RITE HOSPITAL FOR CHILDREN   (United States)

^b Seoul National University Children's Hospital   (South Korea)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^e ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^g Jeju National University   (South Korea)

^h UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Cell tissue signaling transcription factors; Diseases and disorders related to bone other; Human association studies; Molecular pathways development; Tumor induced bone disease

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN P53; PROTEIN TYROSINE KINASE; RAC2 PROTEIN; STEM CELL FACTOR; NEUROFIBROMIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ALLELE; ARTICLE; BLOOD; BONE REMODELING; CARCINOGENESIS; CELL CULTURE; CELL POPULATION; CELL PROLIFERATION; CHROMOSOME 17; CONTROLLED STUDY; DNA EXTRACTION; EXON; FRACTURE HEALING; FRAMESHIFT MUTATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE ONTOLOGY; GENOTYPE; HOMOZYGOSITY; HUMAN; ILIAC CREST; MICROARRAY ANALYSIS; MISSENSE MUTATION; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS TYPE 1; NEUROFIBROMIN DEFICIENCY; NONSENSE MUTATION; ONCOGENE; PROTEIN DEFICIENCY; PSEUDARTHROSIS; SALIVA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TIBIA FRACTURE; TIBIAL PSEUDARTHROSIS; TUMOR GROWTH; UPREGULATION; ADOLESCENT; DEFICIENCY; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; INFANT; MALE; METABOLISM; NEUROFIBROMATOSIS 1; PATHOLOGY; PRESCHOOL CHILD; TIBIAL FRACTURES;

ADOLESCENT; BONE REMODELING; CHILD, PRESCHOOL; FEMALE; FRACTURE HEALING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INFANT; MALE; MAP KINASE SIGNALING SYSTEM; NEUROFIBROMATOSIS 1; NEUROFIBROMIN 1; PHOSPHATIDYLINOSITOL 3-KINASES; PSEUDARTHROSIS; TIBIAL FRACTURES; TRANSCRIPTION, GENETIC;

EID: 84918500136     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.2298     Document Type: Article

References (26)

1. Ballester R, Marchuk D, Boguski M, et al. The NF1 locus encodes a protein functionally related to mammalian GAP and yeast IRA proteins. Cell. 1990;63(4): 851-9.
2. Xu GF, Lin B, Tanaka K, et al. The catalytic domain of the neurofibromatosis type 1 gene product stimulates ras GTPase and complements ira mutants of S. cerevisiae. Cell. 1990;63(4): 835-41.
3. Cichowski K, Jacks T. NF1 tumor suppressor gene function: Narrowing the GAP. Cell. 2001;104(4): 593-604.
4. Stevenson DA, Little D, Armstrong L, et al. Approaches to treating NF1 tibial pseudarthrosis: Consensus from the Children's Tumor Foundation NF1 Bone Abnormalities Consortium. J Pediatr Orthop. 2013; 33(3): 269-75.
5. Elefteriou F, Kolanczyk M, Schindeler A, et al. Skeletal abnormalities in neurofibromatosis type 1: Approaches to therapeutic options. Am J Med Genet A. 2009;149A(10): 2327-38.
6. Stevenson DA, Birch PH, Friedman JM, et al. Descriptive analysis of tibial pseudarthrosis in patients with neurofibromatosis 1. Am J Med Genet. 1999;84(5): 413-9.
7. Stevenson DA, Zhou H, Ashrafi S, et al. Double inactivation of NF1 in tibial pseudarthrosis. Am J Hum Genet. 2006;79(1): 143-8.
8. Lee SM, Choi IH, Lee DY, et al. Is double inactivation of the Nf1 gene responsible for the development of congenital pseudarthrosis of the tibia associated with NF1? J Orthop Res. 2012;30(10): 1535-40.
9. Li H, Durbin R. Fast and accurate short read alignment with Burrows- Wheeler transform. Bioinformatics. 2009;25(14): 1754-60.
10. McKenna A, Hanna M, Banks E, et al. The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20(9): 1297-303.
11. Li H, Handsaker B, Wysoker A, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 2009;25(16): 2078-9.
12. Robinson MD, McCarthy DJ, Smyth GK. edgeR: A bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1): 139-40.
13. Lo HW. Nuclear mode of the EGFR signaling network: Biology, prognostic value, and therapeutic implications. Discov Med. 2010; 10(50): 44-51.
14. Sharma R, Wu X, Rhodes SD, et al. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice. Hum Mol Genet. 2013;22(23): 4818-28.
15. Le LQ, Shipman T, Burns DK, Parada LF. Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas. Cell Stem Cell. 2009;4(5): 453-63.
16. Carragee EJ, Hurwitz EL, Weiner BK. A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: Emerging safety concerns and lessons learned. Spine J. 2011; 11(6): 471-91.
17. Sapkota G, Alarcon C, Spagnoli FM, Brivanlou AH, Massague J. Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol Cell. 2007;25(3): 441-54.
18. Biver E, Soubrier AS, Thouverey C, et al. Fibroblast growth factor 2 inhibits up-regulation of bone morphogenic proteins and their receptors during osteoblastic differentiation of human mesenchymal stem cells. Biochem Biophys Res Commun. 2012;427(4): 737-42.
19. Perry A, Kunz SN, Fuller CE, et al. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol. 2002;61(8): 702-9.
20. Williams JP, Wu J, Johansson G, et al. Nf1 mutation expands an EGFRdependent peripheral nerve progenitor that confers neurofibroma tumorigenic potential. Cell Stem Cell. 2008;3(6): 658-69.
21. Kohli L, Kaza N, Lavalley NJ, et al. The pan erbB inhibitor PD168393 enhances lysosomal dysfunction-induced apoptotic death in malignant peripheral nerve sheath tumor cells. Neuro Oncol. 2012; 14(3): 266-77.
22. Holtkamp N, Malzer E, Zietsch J, et al. EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy. Neuro Oncol. 2008;10(6): 946-57.
23. Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 2007;25(22): 3230-7.
24. Kolanczyk M, Kossler N, Kuhnisch J, et al. Multiple roles for neurofibromin in skeletal development and growth. Hum Mol Genet. 2007;16(8): 874-86.
25. Wang W, Nyman JS, Ono K, Stevenson DA, Yang X, Elefteriou F. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Hum Mol Genet. 2011;20(20): 3910-24.
26. Ingram DA, Hiatt K, King AJ, et al. Hyperactivation of p21(ras) and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med. 2001;194(1): 57-69.